<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625153</url>
  </required_header>
  <id_info>
    <org_study_id>18C013</org_study_id>
    <nct_id>NCT04625153</nct_id>
  </id_info>
  <brief_title>RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial</brief_title>
  <official_title>RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the safety and effectivity of a Recombinant Human B Lymphocyte Stimulator Receptor&#xD;
      : Immunoglobulin G( IgG ) Fc Fusion Protein for injection (RC18) in patients with relapsing&#xD;
      remitting multiple sclerosis, analyze the dose-response relationship and provide a dose basis&#xD;
      for follow-up clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number changes of gadolinium enhanced T1 lesions in the brain</measure>
    <time_frame>At 12, 24, 36, and 48 weeks</time_frame>
    <description>Number changes of gadolinium enhanced T1 lesions in the brain at 12, 24, 36, and 48 weeks compared with baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume changes of gadolinium enhanced T1 lesions</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
    <description>Volume changes of gadolinium enhanced T1 lesions at 12, 24, 36 and 48 weeks compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number changes of new low signal T1 lesions</measure>
    <time_frame>At week 12, 24, 36, and 48 weeks</time_frame>
    <description>Number changes of new low signal T1 lesions at week 12, 24, 36, and 48 weeks compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number changes of new / increased T2 lesions in the brain</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
    <description>Number changes of new / increased T2 lesions in the brain at 12, 24, 36 and 48 weeks compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume changes of T2 lesions in brain</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
    <description>Volume changes of T2 lesions in brain at 12, 24, 36 and 48 weeks compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who did not recur</measure>
    <time_frame>Between 0 and 48 weeks</time_frame>
    <description>Proportion of patients who did not recur between 0 and 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>0-48weeks</time_frame>
    <description>Annual recurrence rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>RC18 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RC18 160mg is injected subcutaneously once a week for 48 times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC18 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RC18 240mg is injected subcutaneously once a week for 48 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 160mg</intervention_name>
    <description>RC18 160mg is injected subcutaneously once a week for 48 times.</description>
    <arm_group_label>RC18 160mg</arm_group_label>
    <other_name>telitacicept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 240mg</intervention_name>
    <description>RC18 240mg is injected subcutaneously once a week for 48 times.</description>
    <arm_group_label>RC18 240mg</arm_group_label>
    <other_name>telitacicept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with relapsing remitting multiple sclerosis meet the diagnostic criteria of&#xD;
             McDonald 2017.&#xD;
&#xD;
          -  18-55 years old, male or female&#xD;
&#xD;
          -  At least 2 recurrences (including clinical recurrence and imaging recurrence) were&#xD;
             recorded within 1 year before randomization.&#xD;
&#xD;
          -  Gadolinium enhanced T1 lesions (≥ 1) in the brain at the screening stage&#xD;
&#xD;
          -  EDSS score ≤ 5.5&#xD;
&#xD;
          -  Informed consent signed voluntarily&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with multiple sclerosis over 5 years&#xD;
&#xD;
          -  Those who are unable to perform MRI or who are allergic to gadolinium contrast agent&#xD;
             during the test&#xD;
&#xD;
          -  In addition to multiple sclerosis, patients with chronic active immune system disease&#xD;
             or stable condition but requiring immunotherapy (glucocorticoids and / or&#xD;
             immunosuppressants) (such as rheumatoid arthritis, scleroderma, Sjogren's syndrome,&#xD;
             Crohn's disease, ulcerative colitis, etc.) or known immune deficiency syndrome (AIDS,&#xD;
             genetic immune deficiency and drug-induced immunity) Patients who used glucocorticoid&#xD;
             maintenance therapy before randomization could participate in the trial after&#xD;
             discontinuation of the drug&#xD;
&#xD;
          -  Patients with Aquaporin 4 (AQP4) antibody positive and / or Myelin oligodendrocyte&#xD;
             glycoprotein(MOG) antibody positive within 1 year before randomization&#xD;
&#xD;
          -  Patients who have received the following treatment:&#xD;
&#xD;
               1. Interferon, pegylated interferon, galatirel acetate, dimethyl fumarate were used&#xD;
                  within 4 weeks before randomization.&#xD;
&#xD;
               2. Fengomod, IV immunoglobulin or plasma exchange within 12 weeks before&#xD;
                  randomization.&#xD;
&#xD;
               3. Alemtuzumab, daclizumab and ocrelizumab were used within 24 weeks before&#xD;
                  randomization.&#xD;
&#xD;
               4. Before randomization, azathioprine (AZA, half-life t1/2 = 6hrs), mycophenolate&#xD;
                  mofetil (t1/2 = 16hrs), leflunomide (LEF, t1/2 = 14.7hrs), tacrolimus (t1/2 =&#xD;
                  43hrs), teriflunomide (t1/2 = 18 days), cyclosporin, In addition to leflunomide&#xD;
                  and telifluoramine, immunosuppressants such as CSA, t1/2 = 27 hrs, methotrexate&#xD;
                  (MTX, t1/2 = 14 HRS), cyclophosphamide (CTX, t1/2 = 6 hrs) can be added to the&#xD;
                  group after the interval of withdrawal is more than 5 times of half-life.&#xD;
                  Leflunomide and tertiazem need to be eluted with coleridine. The drug can be&#xD;
                  stopped and the following measures can be taken: Take 8 g of coleridine three&#xD;
                  times a day for 11 days. If the dose of 8 g can not be tolerated, it can be&#xD;
                  changed to 4 g each time. The time and times are the same as before.&#xD;
&#xD;
               5. Cladribine or mitoxantrone was used within 1 year before randomization.&#xD;
&#xD;
               6. Lymphoid irradiation and bone marrow transplantation were received before&#xD;
                  randomization.&#xD;
&#xD;
          -  Patients were participated in any clinical trial 28 days before randomization or&#xD;
             within 5 times half-life of study drug participating in clinical trial (whichever is&#xD;
             longer).&#xD;
&#xD;
          -  Patients with any persistent or chronic active infection or serious infection history&#xD;
             in the screening period, such as shingles; active tuberculosis (patients with latent&#xD;
             tuberculosis can participate in the test if they are given isoniazid and / or rifampin&#xD;
             at the same time); HIV infection; syphilis antibody positive; HCV antibody positive;&#xD;
             HBsAg positive; HBsAg negative but HBcAb positive, the HBV-DNA quantitative test is&#xD;
             needed. If the HBV-DNA is positive, the patient should be excluded. If the HBV-DNA is&#xD;
             negative, the patient can not be excluded.&#xD;
&#xD;
          -  The results of abnormal laboratory tests to be excluded include but are not limited&#xD;
             to: Leukocyte count &lt; 3 × 10~9 / L; neutrophil &lt; 1.5 × 10~9 / L; hemoglobin &lt; 85g / L;&#xD;
             platelet count &lt; 80 × 10~9 / L; serum creatinine &gt; 1.5 × ULN, accompanied by&#xD;
             creatinine clearance &lt; 50ml / min (measured value, or calculated by Cockcroft Gault&#xD;
             formula); total bilirubin &gt; 1.5 × ULN; ALT &gt; 3 × ULN; AST &gt; 3 × ULN; alkaline&#xD;
             phosphatase &gt; 2 × ULN; IgG &lt; lower limit of normal value; IgM &lt; lower limit of normal&#xD;
             value;&#xD;
&#xD;
          -  Cancer patients&#xD;
&#xD;
          -  Pregnant women, lactating women and patients with family planning during the trial&#xD;
&#xD;
          -  Patients with other mental disorders&#xD;
&#xD;
          -  Patients who experienced any of the following events within 12 weeks before&#xD;
             randomization: myocardial infarction, unstable ischemic heart disease, stroke, or NYHA&#xD;
             class IV heart failure&#xD;
&#xD;
          -  The researchers believe that the patients are compliant insufficiently or not suitable&#xD;
             to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Binghua Xiao</last_name>
    <phone>86-010-58076833</phone>
    <email>Binghua.xiao@remegen.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Third Affiliated Hospital,Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Qiu, MD</last_name>
      <phone>02085253032</phone>
      <email>qiuwei120@vip.163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

